Trial Profile
An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Dec 2018 Results presented in a novatis media release.
- 21 Sep 2018 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Planned End Date changed from 8 May 2018 to 28 Nov 2018.